Pitavastatin

Generic Name: Pitavastatin

Brand Names: Livalo, Zypitamag

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₂₄FNO_₄

CAS Number: 147511-69-1

Unique Ingredient Identifier: M5681Q5F9P

Background: Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competiti...

Indication: 用于治疗高胆固醇症(高脂血症)、家族性高胆固醇症。

Associated Conditions: Apolipoprotein B increased, Elevation of serum triglyceride levels, Increases in serum total low-density lipoprotein (LDL), Increases in total cholesterol

Associated Therapies: -

Clinical Trials

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Phase 3

Completed

Conditions: HIV
Cardiovascular Diseases

Interventions: Drug: Pitavastatin
Drug: Placebo

First Posted Date: 2015-01-22

Last Posted Date: 2024-10-18

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 7769

Registration Number: NCT02344290

Locations: 🇺🇸
Alabama CRS*, Birmingham, Alabama, United States
🇺🇸
University of Southern California CRS*, Los Angeles, California, United States
🇺🇸
UCLA CARE Center CRS*, Los Angeles, California, United States

and more 134 locations

Effects of Pitavastatin on Insulin Sensitivity and Liver Fat

Not Applicable

Completed

Conditions: Obesity
Fatty Liver, Nonalcoholic

Interventions: Drug: pitavastatin
Other: PLACEBO

First Posted Date: 2014-11-13

Last Posted Date: 2019-07-02

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 50

Registration Number: NCT02290106

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Effect of Pitavastatin on Coronary Flow Reserve in Hypertensive Patients

Phase 4

Completed

Conditions: Hypertension
Cardiovascular Risk

Interventions: Drug: Pitavastatin
Other: Control

First Posted Date: 2014-05-22

Last Posted Date: 2016-10-14

Lead Sponsor: Asan Medical Center

Target Recruit Count: 85

Registration Number: NCT02144922

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Preventive Effect of Pitavastatin on Contrast-Induced Nephropathy in Patients With Renal Dysfunction

Phase 4

Conditions: Contrast-induced Nephropathy

Interventions: Drug: Placebo
Drug: Pitavastatin

First Posted Date: 2013-06-07

Last Posted Date: 2013-06-07

Lead Sponsor: Gachon University Gil Medical Center

Target Recruit Count: 404

Registration Number: NCT01871792

Locations: 🇰🇷
Gachon University Gil Hospital, Incheon, Korea, Republic of

Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz

Phase 1

Completed

Conditions: HIV
Hyperlipidemia

Interventions: Drug: Pitavastatin
Drug: Efavirenz
Drug: Darunavir
Drug: Ritonavir

First Posted Date: 2012-09-28

Last Posted Date: 2020-08-11

Lead Sponsor: NYU Langone Health

Target Recruit Count: 34

Registration Number: NCT01695954

Locations: 🇺🇸
Bellevue/NYU AIDS Clinical Trials Unit, New York, New York, United States

PharmacOdynamic compaRison of piTavastatin Versus atOrvastatin on Platelet Reactivity

Phase 4

Conditions: Coronary Artery Disease

Interventions: Drug: Atorvastatin
Drug: Pitavastatin

First Posted Date: 2012-07-24

Last Posted Date: 2013-03-07

Lead Sponsor: University of Roma La Sapienza

Target Recruit Count: 100

Registration Number: NCT01648829

Locations: 🇮🇹
Sapienza University, Rome, Italy

Effects of Pitavastatin on Monocyte, Endothelial Dysfunction and HDL-C in Subjects With Metabolic Syndrome

Phase 1

Completed

Conditions: Metabolic Syndrome

Interventions: Drug: Pitavastatin

First Posted Date: 2012-05-10

Last Posted Date: 2013-07-22

Lead Sponsor: Kowa Research Europe

Target Recruit Count: 14

Registration Number: NCT01595828

Locations: 🇬🇧
Kowa Research Europe Ltd., Wokingham, United Kingdom

Efficacy and Safety Study of Pitavastatin and Atorvastatin in High Risk Hypercholesterolemic Patients

Phase 3

Conditions: Hyperlipidemia

Interventions: Drug: Pitavastatin
Drug: Atorvastatin

First Posted Date: 2011-07-01

Last Posted Date: 2011-07-01

Lead Sponsor: Tai Tien Pharmaceuticals Co., Ltd.

Target Recruit Count: 200

Registration Number: NCT01386853

Locations: 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
🇨🇳
Tri-Service General Hospital, Taipei, Taiwan
🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan

and more 3 locations

A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects

Phase 4

Completed

Conditions: Dyslipidemia

Interventions: Drug: Pitavastatin
Drug: Pravastatin

First Posted Date: 2011-02-23

Last Posted Date: 2014-04-29

Lead Sponsor: Kowa Research Institute, Inc.

Target Recruit Count: 252

Registration Number: NCT01301066

Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia

Phase 4

Completed

Conditions: Primary Dyslipidemia
Mixed Dyslipidemia

Interventions: Drug: pitavastatin
Drug: pravastatin

First Posted Date: 2010-12-08

Last Posted Date: 2012-05-08

Lead Sponsor: Kowa Research Institute, Inc.

Target Recruit Count: 328

Registration Number: NCT01256476

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy